Jan 27 (Reuters) - Alexandria Real Estate Equities ARE.N posted a rise in its fourth-quarter funds from operations on Monday, as the real estate investment trust benefited from steady leasing demand from biotech clients and technology-focused firms.
The Pasadena, California-based company operates and develops life science laboratories, offices and technology campuses across North America.
Its clients include Bristol Myers Squibb BMY.N, Moderna MRNA.O and Eli Lilly LLY.N, as well as agricultural tech companies and research institutions.
Occupancy of Alexandria's operating properties held steady at 94.6% as of Dec. 31, compared with the year earlier.
FFO, a key performance measure for REITs, came in at $411.8 million, or $2.39 per share, for the quarter, compared with $389.8 million, or $2.28 per share, a year ago.
Its total revenue for the quarter rose 4.2% to $788.9 million.
(Reporting by Aatreyee Dasgupta and Nathan Gomes in Bengaluru; Editing by Shilpi Majumdar)
((Aatreyee.Dasgupta@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.